α<sub>1</sub>-Adrenoceptor Subtypes and α<sub>1</sub>-Adrenoceptor Antagonists

  • MURAMATSU Ikunobu
    Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine
  • SUZUKI Fumiko
    Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine
  • TANAKA Takashi
    Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine
  • YAMAMOTO Hatsumi
    Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine
  • MORISHIMA Shigeru
    Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, University of Fukui School of Medicine

Bibliographic Information

Other Title
  • α<sub>1</sub>アドレナリン受容体の分類とα<sub>1</sub>遮断薬の最新情報
  • α1アドレナリン受容体の分類とα1遮断薬の最新情報
  • アルファ 1 アドレナリン ジュヨウタイ ノ ブンルイ ト アルファ 1 シャダンヤク ノ サイシン ジョウホウ
  • &alpha;<sub>1</sub>-Adrenoceptor Subtypes and &alpha;<sub>1</sub>-Adrenoceptor Antagonists
  • α_1-Adrenoceptor Subtypes and α_1-Adrenoceptor Antagonists

Search this article

Abstract

  α1-adrenoceptors are widely distributed in the human body and play important physiologic roles. Three α1-adrenoceptor subtypes (α1A, α1B and α1D) have been cloned and show different pharmacologic profiles. In addition, a putative α1-adrenoceptor (α1L subtype) has also been proposed. Recently, three drugs (tamsulosin, naftopidil, and silodosin) have been developed in Japan for the treatment of urinary obstruction in patients with benign prostatic hyperplasia. In this review, we describe recent α1-adrenoceptor subclassifications and the pharmacologic characteristics (subtype selectivity and clinical relevance) of α1-adrenoceptor antagonists.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 126 (Special_Issue), 187-198, 2006

    The Pharmaceutical Society of Japan

Citations (5)*help

See more

References(31)*help

See more

Related Projects

See more

Report a problem

Back to top